Christopher Ryan Sullivan Sells $1.45M of Avalo Therapeutics Inc (AVTX) — SEC Form 4, Aug 19, 2026
Open-Market Net Sale · SEC Form 4
−$1,450,419
10b5-1 Plan (Partial)
Equity position changed by -2.1%
Equity Position
39.9K sh
40,773 → 39,900
Equity Change
-2.1%
shares held after vs before
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Christopher Ryan Sullivan CIK 0001810417 |
CFO
|
Christopher Ryan Sullivan at Avalo Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$3,723,035
More from this insider at Avalo Therapeutics Inc
| 2026-09-18 | Sell | -$202,437 | View |
| 2026-09-11 | Sell | -$179,457 | View |
| 2026-06-12 | - | — | View |
| 2026-05-26 | Award | — | View |
| 2026-05-11 | Sell | -$448,818 | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1 | 2026-08-17 | M - Exercise 10b5-1 | 37,945 A | $9.88 | +$374,897 | 78,718 | Direct |
| Common Stock | 2026-08-17 | M - Exercise 10b5-1 | 2,876 A | $9.88 | +$28,415 | 81,594 | Direct |
| Common StockF1F2 | 2026-08-17 | S - Sale 10b5-1 | 37,945 D | $19.85 | -$753,333 | 43,649 | Direct |
| Common StockF3 | 2026-08-17 | S - Sale | 3,749 D | $19.94 | -$74,762 | 39,900 | Direct |
| Common Stock | 2026-08-18 | M - Exercise 10b5-1 | 31,031 A | $9.88 | +$306,586 | 70,931 | Direct |
| Common StockF4 | 2026-08-18 | S - Sale | 31,031 D | $20.05 | -$622,324 | 39,900 | Direct |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1F5 | $9.88 | 2026-08-17 | M - Exercise 10b5-1 | 37,945 D | $0.00 | 2034-08-13 | 37,945 Common Stock | Direct |
| Stock Option (Right to Buy)F5 | $9.88 | 2026-08-17 | M - Exercise | 2,876 D | $0.00 | 2034-08-13 | 2,876 Common Stock | Direct |
| Stock Option (Right to Buy)F5 | $9.88 | 2026-08-18 | M - Exercise | 31,031 D | $0.00 | 2034-08-13 | 31,031 Common Stock | Direct |
Footnotes (5)
- F1
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. Show more
- F2
- The reported securities were sold in multiple transactions at prices ranging from $19.16 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Show more
- F3
- The reported securities were sold in multiple transactions at prices ranging from $19.70 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Show more
- F4
- The reported securities were sold in multiple transactions at prices ranging from $20.00 to $20.265. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Show more
- F5
- The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date. Show more
Related filings at Avalo Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
125
institutional managers reporting a position
Largest by reported value
- Fmr Llc $94.3M
- Black Rock, Inc. $80.7M
- Deep Track Capital, Lp $66.7M
5%+ Holders · 13D/G
12 filers
Other insiders at Avalo Therapeutics Inc
GET /v1/forms/4/0001810417-26-000019
API docs
View Original SEC Filing